

AMENDMENTS TO THE CLAIMS

1 - 124. (CANCELED).

125. (PREVIOUSLY PRESENTED) A pharmaceutical dosage form comprising said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate and a pharmaceutically acceptable carrier or diluent; wherein said crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum comprising at least one peak with chemical shift of about 179.5 ppm.

126-127. (CANCELED)

128. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 178.6 ppm.

129. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 128, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 58.0 ppm.

130. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 129, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 17.2 ppm.

131. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 130, wherein said substantially pure crystalline azithromycin monohydrate

hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 10.1 ppm.

132. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 131, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 9.8 ppm.

133. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 132, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 9.3 ppm.

134. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 133, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 7.9 ppm.

135 (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 134, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a  $^{13}\text{C}$  solid state NMR spectrum further comprising a peak with chemical shifts of about 6.6 ppm.

136. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 82% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

137 (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate

hemi-ethanol solvate comprises 84% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

138. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 86% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

139. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 88% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

140. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 90% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

141. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 94% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

142. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 98% or more by weight of form F azithromycin.

143. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 99% or more by weight of form F azithromycin.

144. (PREVIOUSLY PRESENTED) The pharmaceutical dosage form of claim 125,  
wherein said dosage form comprises from about 1.0% to about 70% of  
substantially pure crystalline azithromycin monohydrate hemi-ethanol  
solvate.